Navigation Links
Lorus initiates development program exploring novel route of administration for LOR-2040
Date:4/22/2008

ical, clinical and regulatory expertise by developing new drugs that can be used, either alone, or in combination with other agents, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements or transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, security holder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
4. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
5. SemBioSys initiates toxicology study for safflower-produced insulin
6. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
7. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
10. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
11. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management ... Product Strategy. In this role, Michelle will work with current ... in the development of iLab products. Her main goal will ... to the scientific community by offering the most advanced, user-friendly, ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... Up, Net Loss Down, Cash Position Strong, as Pipeline ... Continues to ... EXEL ) today reported financial results for the full,year and fourth quarter ... compared to $98.7 million in,2006. The increase in revenues for the full ...
... Revenue Increased 69.8% to $7.7 million ... - Second Quarter Net Income Increased 67.5% to $1.7 million, - First Six Months Revenues ... Increased 65% to $3.2 million for the Same Period, - Growth Driven ... ...
... Afford Life-Saving Biopharmaceuticals, WASHINGTON, Feb. 14 ... legislation that would create a pathway for,FDA approval ... new print,advertisement that features a footprint in the ... The ad highlights how meaningful biogenerics legislation ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 8
(Date:4/17/2014)... Cell Press journal Current Biology on April ... sex lives. The Brazilian insects, which represent four distinct ... are the first example of an animal with sex-reversed ... in several different animals, Neotrogla is the ... reversed," says Kazunori Yoshizawa from Hokkaido University in Japan. ...
(Date:4/17/2014)... the immune system may fight cancers and viral infections. ... to treat illness. , The research, in mice, suggests ... police" specialized squads of defenders that patrol only ... city, the body. , Scientists at Washington University School ... liver, skin and uterus each has dedicated immune cells, ...
(Date:4/16/2014)... museum collections two new species of yellow-shouldered bats have been unearthed ... Field Museum of Natural History and described in the open access ... the genus Sturnira are part of a recent discovery ... third one still waiting to be officially announced. , Up until ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Some immune cells defend only 1 organ 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... may help us think, in addition to its well-known ... brain cells. We hypothesize that blood ... a principle investigator in the McGovern Institute for Brain ... Journal of Neurophysiology. Many lines of evidence suggest that ...
... the jungles of Central and South America, a group ... food by following hordes of army ants and ... curator of genetic resources at the LSU Museum of ... witnessed this peculiarity in 1989 when he accompanied then-LSU ...
... have seen the potential for cleaning up contaminated sites by ... their roots. Then the plants break certain kinds of pollutants ... roots, stems and leaves or release into the air. The ... that the process is slow and halts completely when growth ...
Cached Biology News:MIT: blood may help us think 2LSU professor studies army-ant-following birds 2Scientists ramp up ability of poplar plants to disarm toxic pollutants 2Scientists ramp up ability of poplar plants to disarm toxic pollutants 3Scientists ramp up ability of poplar plants to disarm toxic pollutants 4
... Continuous flow of media and other ... little lab space, The speed of each ... and flow set points, are exactly maintained. ... equipped with variable tube types, which allows ...
... The SearchLight® IR Mouse Cytokine Array is ... for the quantitative measurement of 12 cytokines ... and culture supernatants. Each well of the ... capture specific cytokines in standards and samples ...
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... PRO S-7 stirrers deliver accurate ... channels fluids away from internal ... easy-to-use controls which allow users ... ceramic tops feature a chemical ...
Biology Products: